Bluebird Bio

Pharma

Vertex gains FDA expansion of Casgevy to those ages 2 and older

The FDA has granted a label expansion for children ages 2 and up to receive Vertex's gene therapy Casgevy for sickle cell disease or beta thalassemia.

Kevin Dunleavy Jul 6, 2026 11:30am

FDA signs off on expansion for Gamida Cell's Omisirge

Dec 9, 2025 8:19am

Bluebird bio hatches new branding as Genetix Biotherapeutics

Sep 18, 2025 10:32am

FDA restricts bluebird's gene therapy after blood cancer reports

Aug 8, 2025 11:19am

bluebird investors get on board with sale to Carlyle, SK Capital

May 30, 2025 11:50am

Bluebird investor reluctance pays off with better buyout offer

May 14, 2025 10:40am